Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - PharmaNetics, Inc. (NasdaqNM:PHAR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
July 31Conference call: PharmaNetics Earnings (Q2 2001)
Location
9401 Globe Center Drive, Suite 140
Morrisville, NC 27560
Phone: (919) 582-2600
Email: pstorey@pharmanetics.com
Employees (last reported count): 91
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 40%
·Institutional: 16% (27% of float)
(26 institutions)
·Net Inst. Buying: 126.0K shares (+7.57%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
PharmaNetics, Inc., through its wholly owned subsidiary Cardiovascular Diagnostics, Inc. (CVDI), develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. CVDI's products include a proprietary analyzer and dry chemistry tests, known as the Thrombolytic Assessment System, which provides, at the point of patient care, rapid and accurate evaluation of hemostasis. CVDI is also establishing itself in the emerging field of theranostics, or rapid near-patient testing, in which the diagnostic results may influence treatment decisions. CVDI's current tests and tests under development are used in the treatment of angina, heart attack, stroke, deep vein thrombosis and pulmonary and arterial emboli.
More from Market Guide: Expanded Business Description

Financial Summary
PharmaNetics, Inc., a holding company, develops, markets and manufactures a proprietary cardiovascular diagnostic test system that provides rapid and accurate evaluation of hemostasis at the point of patient care. For the three months ended 3/31/01, revenues fell 46% to $802 thousand. Net loss applicable to Common rose 29% to $1.9 million. Revenues reflect lower sales of analyzers to Bayer. Higher losses reflect headcount additions and budget increases.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 1,322; after tax earnings were -2,333. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

John Funkhouser, 46
Chairman, Pres, CEO
$236K
Michael Riddle, 46
Exec. VP of Sales, Marketing and Bus. Devel.
165K
Dick Timmons, II, 54
VP- Manufacturing and COO
147K
Peter Scott, 51
VP of Quality Assurance and Regulatory Affairs
126K
Mark Triscott, Ph.D.
VP-R&D
--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PHARAs of 31-Aug-2001
Price and Volume
52-Week Low
on 4-Apr-2001
$6.50 
Recent Price$8.00 
52-Week High
on 5-Sep-2000
$23.188
Beta1.29 
Daily Volume (3-month avg)8,409 
Daily Volume (10-day avg)6,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.1%
52-Week Change
relative to S&P500
-49.2%
Share-Related Items
Market Capitalization$74.6M
Shares Outstanding9.32M
Float5.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$0.50 
Earnings (ttm)-$1.35 
Earnings (mrq)-$0.28 
Sales (ttm)$0.45 
Cash (mrq*)$0.53 
Valuation Ratios
Price/Book (mrq*)16.05 
Price/EarningsN/A 
Price/Sales (ttm)17.94 
Income Statements
Sales (ttm)$3.53M
EBITDA (ttm*)-$7.34M
Income available to common (ttm)-$10.7M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-43.66%
Return on Equity (ttm)-153.90%
Financial Strength
Current Ratio (mrq*)3.15 
Debt/Equity (mrq*)0.17 
Total Cash (mrq)$18.6M
Short Interest
As of 8-Aug-2001
Shares Short276.0K
Percent of Float4.9%
Shares Short
(Prior Month)
287.0K
Short Ratio30.67 
Daily Volume9,000 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.